journal article·2021-05-10Open access

Prolonged Codelivery of Hemagglutinin and a TLR7/8 Agonist in a Supramolecular Polymer–Nanoparticle Hydrogel Enhances Potency and Breadth of Influenza Vaccination

Gillie A. Roth, Olivia M. Saouaf, Anton A. A. Smith, Emily C. Gale, Marcela Alcántara Hernández, Juliana Idoyaga, Eric A. Appel

Abstract

The sustained release of vaccine cargo has been shown to improve humoral immune responses to challenging pathogens such as influenza. Extended codelivery of antigen and adjuvant prolongs germinal center reactions, thus improving antibody affinity maturation and the ability to neutralize the target pathogen. Here, we develop an injectable, physically cross-linked polymer-nanoparticle (PNP) hydrogel system to prolong the local codelivery of hemagglutinin and a toll-like receptor 7/8 agonist (TLR7/8a) adjuvant. By tethering the TLR7/8a to a NP motif within the hydrogels (TLR7/8a-NP), the dynamic mesh of the PNP hydrogels enables codiffusion of the adjuvant and protein antigen (hemagglutinin), therefore enabling sustained codelivery of these two physicochemically distinct molecules. We show that subcutaneous delivery of PNP hydrogels carrying hemagglutinin and TLR7/8a-NP in mice improves the magnitude and duration of antibody titers in response to a single injection vaccination compared to clinically used adjuvants. Furthermore, the PNP gel-based slow delivery of influenza vaccines led to increased breadth of antibody responses against future influenza variants, including a future pandemic variant, compared to clinical adjuvants. In summary, this work introduces a simple and effective vaccine delivery platform that increases the potency and durability of influenza subunit vaccines.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Influenza Virus Research Studies · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering, Stanford University, 443 Via Ortega, Stanford, California 94305, United States

Department of Materials Science & Engineering, Stanford University, 496 Lomita Mall, Stanford, California 94305, United States

Department of Biochemistry, Stanford University School of Medicine, 279 Campus Drive, Stanford, California 94305, United States

Department of Microbiology & Immunology, Stanford University School of Medicine, 299 Campus Drive, Stanford, California 94305, United States

Program in Immunology, Stanford University School of Medicine, 240 Pasteur Drive, Stanford, California 94305, United States

Institute for Immunity, Transplantation & Infection, Stanford University School of Medicine, 240 Pasteur Drive, Stanford, California 94305, United States

ChEM-H Institute, Stanford University, 290 Jane Stanford Way, Stanford, California 94305, United States

Department of Pediatrics - Endocrinology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305, United States

Funding

Novo Nordisk Fonden · Bill and Melinda Gates Foundation · American Cancer Society

References (53)

Show source-provided references
1. 10.3389/fcimb.2018.0034310.3389/fcimb.2018.00343 ↗
2. 10.1073/pnas.192118611710.1073/pnas.1921186117 ↗
3. 10.1126/scitranslmed.300376310.1126/scitranslmed.3003763 ↗
4. 10.1016/j.coi.2015.06.00710.1016/j.coi.2015.06.007 ↗
5. 10.1016/bs.ai.2016.11.00210.1016/bs.ai.2016.11.002 ↗
6. 10.1016/j.cell.2013.03.01810.1016/j.cell.2013.03.018 ↗
7. 10.1016/j.immuni.2019.04.01110.1016/j.immuni.2019.04.011 ↗
8. 10.1172/JCI8108310.1172/JCI81083 ↗
9. 10.1016/j.addr.2020.06.01910.1016/j.addr.2020.06.019 ↗
10. 10.1016/j.immuni.2014.10.00410.1016/j.immuni.2014.10.004 ↗
11. 10.1016/j.copbio.2019.01.01010.1016/j.copbio.2019.01.010 ↗
12. 10.1172/JCI3929310.1172/JCI39293 ↗
13. 10.1038/nature0973710.1038/nature09737 ↗
14. 10.1371/journal.pone.008388410.1371/journal.pone.0083884 ↗
15. 10.1021/jacs.5b0997410.1021/jacs.5b09974 ↗
16. 10.1038/natrevmats.2016.7110.1038/natrevmats.2016.71 ↗
17. 10.1002/adfm.20120151210.1002/adfm.201201512 ↗
18. 10.1038/nmat377510.1038/nmat3775 ↗
19. 10.1073/pnas.160605011310.1073/pnas.1606050113 ↗
20. 10.1021/acscentsci.0c0073210.1021/acscentsci.0c00732 ↗
21. 10.1073/pnas.190217911610.1073/pnas.1902179116 ↗
22. 10.1016/j.cell.2019.04.01210.1016/j.cell.2019.04.012 ↗
23. 10.1021/acsbiomaterials.7b0056110.1021/acsbiomaterials.7b00561 ↗
24. 10.1002/adhm.20120043510.1002/adhm.201200435 ↗
25. 10.1016/j.jconrel.2018.09.02010.1016/j.jconrel.2018.09.020 ↗
26. 10.1038/nbt.337110.1038/nbt.3371 ↗
27. 10.1038/s41578-019-0110-710.1038/s41578-019-0110-7 ↗
28. 10.1002/adtp.20190017410.1002/adtp.201900174 ↗
29. 10.1021/acs.biomac.0c0081210.1021/acs.biomac.0c00812 ↗
30. 10.1016/j.biomaterials.2012.02.03010.1016/j.biomaterials.2012.02.030 ↗
31. 10.1002/adhm.20150061810.1002/adhm.201500618 ↗
32. 10.1039/C1SM06513K10.1039/C1SM06513K ↗
33. 10.1021/bm401280z10.1021/bm401280z ↗
34. 10.1016/j.cyto.2019.15497410.1016/j.cyto.2019.154974 ↗
35. 10.1038/nmat447410.1038/nmat4474 ↗
36. 10.1039/c2cs35264h10.1039/c2cs35264h ↗
37. 10.1038/ncomms729510.1038/ncomms7295 ↗
38. 10.1039/C7BM00780A10.1039/C7BM00780A ↗
39. 10.1038/s41551-019-0442-z10.1038/s41551-019-0442-z ↗
40. 10.1002/mabi.20180027510.1002/mabi.201800275 ↗
41. 10.1021/acsmacrolett.5b0041610.1021/acsmacrolett.5b00416 ↗
42. 10.1073/pnas.161815611310.1073/pnas.1618156113 ↗
43. 10.1073/pnas.190785511610.1073/pnas.1907855116 ↗
44. 10.1002/adhm.20180114710.1002/adhm.201801147 ↗
45. 10.1016/j.biomaterials.2014.08.00110.1016/j.biomaterials.2014.08.001 ↗
46. 10.1002/pola.2939310.1002/pola.29393 ↗
47. 10.1016/S0006-3495(76)85755-410.1016/S0006-3495(76)85755-4 ↗
48. 10.1002/btm2.1014710.1002/btm2.10147 ↗
49. 10.1021/acs.biomac.9b0112910.1021/acs.biomac.9b01129 ↗
50. 10.1080/21645515.2017.141568410.1080/21645515.2017.1415684 ↗
51. 10.3389/fmicb.2019.0001910.3389/fmicb.2019.00019 ↗
52. Ezeanolue, E.; Harriman, K.; Hunter, P.; Kroger, A.; Pellegrini, C. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html.
53. 10.1016/S0022-1759(98)00015-510.1016/S0022-1759(98)00015-5 ↗